PURE Bioscience Reports $2.067 Million Net Loss and Decreased Revenue for Nine Months Ending April 30, 2025

PURE Bioscience, Inc. reported its financial results for the nine months ending April 30, 2025, revealing a net loss of $2.067 million on total revenue of $1.438 million. This represents a decrease in revenue compared to the same period in the previous fiscal year, where the company recorded $1.489 million in revenue. The decline in net product sales, which totaled $1.435 million, was attributed to decreased sales across the end-user network, with the top customer contributing $193,000 to net product sales during this period. The company’s gross profit for the nine months was $835,000, down from $877,000 in the prior year, reflecting a gross margin percentage of 58%, slightly lower than the 59% reported for the same period in 2024.

In terms of operational changes, PURE Bioscience saw a significant reduction in selling, general, and administrative expenses, which fell to $2.528 million from $3.136 million year-over-year. This decrease was primarily due to lower personnel costs and professional service fees. Research and development expenses increased slightly to $243,000 from $233,000, indicating ongoing investment in product development. The company also reported an increase in interest expense, which rose to $210,000 from $103,000, largely due to accrued interest on convertible notes.

The company’s balance sheet as of April 30, 2025, showed total assets of $1.057 million, up from $818,000 at the end of the previous fiscal year. Current liabilities increased to $972,000, primarily due to higher accounts payable, which rose to $799,000 from $601,000. The stockholders' deficiency also widened to $4.814 million, compared to $2.864 million in the prior year, reflecting the ongoing challenges in achieving profitability. As of the reporting date, PURE Bioscience had $540,000 in cash and cash equivalents, an increase from $349,000 at the end of July 2024.

Strategically, the company continues to focus on its proprietary antimicrobial products, particularly those based on stabilized ionic silver, which are marketed under the PURE brand. The company aims to expand its distribution network and develop additional proprietary products. Despite the challenges, management remains optimistic about the market opportunities for its SDC-based solutions, particularly in the food industry, where it has established products like PURE® Hard Surface and PURE Control®.

Looking ahead, PURE Bioscience acknowledges the substantial doubt regarding its ability to continue as a going concern due to its history of recurring losses and negative cash flows from operations. The company plans to fund its operations through equity and debt offerings until it can generate positive cash flow. However, management cautions that there is no assurance that additional financing will be available when needed or on favorable terms, which could impact its operational capabilities and growth prospects.